PIFELTRO 100 MG FILM-COATED TABLET
DORAVIRINE
What it does
Doravirine is a medication used to help manage HIV (human immunodeficiency virus) infection.
Commonly used for: HIV infection
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:34:38 · updated 2026-10-20 02:21:41
Drug Interactions
7Severe (1)
Doravirine - decreases exposure
Lumacaftorispredictedtodecreasetheexposureto doravirine.Avoid.rTheoretical
Moderate (2)
Sirolimus - decreases exposure
Doravirine is predicted to decrease the exposure to sirolimus. Monitor sirolimus concentration and adjust dose, p. 919.
Tacrolimus - decreases exposure
Doravirine is predicted to decrease the exposure to tacrolimus. Monitor tacrolimus concentration and adjust dose, p. 920.
Unknown (4)
Doravirine - decreases exposure
Dabrafenib is predicted to decrease the exposure to doravirine. Avoid or adjust doravirine p. 708 or lamivudine with tenofovir disoproxil and doravirine p. 718 dose.
Doravirine - decreases exposure
Mitotaneispredictedtodecreasetheexposuretodoravirine. Avoid.rStudy
Doravirine - decreases exposure
Modafinil is predicted to decrease the exposure to doravirine. Avoid or adjust doravirine p. 708 or lamivudine with tenofovir disoproxil and doravirine p. 718 dose.
Doravirine - decreases exposure
Telotristat ethyl is predicted to decrease the exposure to doravirine. Avoid or adjust doravirine p. 708 or lamivudine with tenofovir disoproxil and doravirine p. 718 dose.
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About this medicine
Doravirine is a medication used to help manage HIV (human immunodeficiency virus) infection.
What it treats
- HIV infection
How it works
It works by preventing the virus from multiplying in the body, helping to control the infection.
Who it's for
Doravirine is for adults and children who are infected with HIV.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Doravirine
BNF-referencedDoravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV-1 infection. It works by inhibiting the reverse transcriptase enzyme, which is crucial for the replication of the virus. By blocking this enzyme, doravirine prevents the conversion of viral RNA into DNA, thereby hindering the virus's ability to replicate within the host's cells. It is typically used in combination with other antiretroviral drugs to enhance treatment efficacy.
Indications
- HIV-1 infection
Dosage
Children: Refer to the BNF for Children for specific paediatric dosing guidelines.
Adults: 600 mg once daily.
Mechanism of action
Doravirine inhibits HIV-1 replication by non-competitively inhibiting the reverse transcriptase enzyme that HIV uses to generate complementary DNA (cDNA) from its RNA genome. This cDNA is then integrated into the host cell genome, allowing for viral replication. Importantly, doravirine does not inhibit human DNA polymerases, ensuring a selective action against HIV-1.
Pharmacodynamics
In clinical trials, doravirine demonstrated efficacy in reducing viral load in HIV-1 infected individuals. A phase 2 trial assessed doses ranging from 0.25 to 2 times the recommended dose and found no significant exposure-response relationship for efficacy, indicating that higher doses do not necessarily equate to better outcomes. Furthermore, doravirine does not significantly affect the QT interval, even at doses significantly higher than the recommended dosage.
Pharmacokinetics
Doravirine is well absorbed after oral administration, with peak plasma concentrations occurring within 1 to 4 hours. The drug has a half-life that allows for once-daily dosing. It is primarily metabolized in the liver via the cytochrome P450 system, particularly CYP3A, and is eliminated mainly through feces, with renal excretion accounting for a minor portion. The presence of certain medications can interact with doravirine, potentially necessitating dose adjustments.
Adverse effects
- Abdominal pain
- Anxiety
- Asthenia
- Diarrhoea
- Dizziness
- Drowsiness
- Gastrointestinal discomfort
- Nausea
- Skin reactions
- Sleep disorders
- Vomiting
- Behavioural abnormality
- Confusion
- Flushing
- Headache
- Hepatocellular injury
- Gynaecomastia
- Hallucination
- Memory reactions
- Mood altered
- Pancreatitis
- Psychosis
- Seizure
- Suicidal behaviours
- Thinking confusion
- Constipation
- Depression
- Electrolyte abnormality
- Tinnitus
- Tremor
- Vertigo
- Blurred vision
- Hypertension
- Malaise
- Memory loss
- Myalgia
- Paresthesia
- Delusions
- Photosensitivity reaction
- Acute kidney injury
Interactions
- Doravirine can decrease the exposure of lumacaftor
- Doravirine can decrease the exposure of sirolimus
- Doravirine can decrease the exposure of tacrolimus
- Doravirine can decrease the exposure of dabrafenib
- Doravirine can decrease the exposure of mitotane
- Doravirine can decrease the exposure of modafinil
- Doravirine can decrease the exposure of telotristatethyl
Precautions
- Caution in patients with acute porphyrias
- Caution in elderly patients
- History of psychiatric disorders
- History of seizures
- Risk of QT interval prolongation in certain individuals
- Caution in patients with abnormal hepatic function
- Monitor liver function if receiving other hepatotoxic drugs
- Caution in renal impairment, particularly severe renal failure
Pregnancy
Manufacturer advises to avoid use due to potential risks, including reports of neural tube defects when used in the first trimester.
Breast-feeding
No information available regarding excretion in breast milk and the effects on the
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Doravirine
PubChem CID 58460047Molecular formula: C17H11ClF3N5O3
Mechanism of action
Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor of HIV-1. Reverse transcriptase is the enzyme with which HIV generates complementary DNA (cDNA) to its RNA genome - this cDNA is then inserted into the host cell genome, where it can be transcribed into viral RNA for the purposes of replication. Doravirine inhibits HIV-1 replication by non-competitively inhibiting HIV-1 reverse transcriptase. Doravirine does not, however, inhibit the human cellular DNA polymerases α, ß, and mitochondrial DNA polymerase γ.
Pharmacodynamics
In a clinical phase 2 trial evaluating a dose range of 0.25-2x the recommended dose of doravirine (in combination with emtricitabine/tenofovir) in HIV-1 infected subjects with no antiretroviral treatment history, no exposure-response relationship for efficacy was identified for doravirine. Furthermore, at a dose of 1200 mg, which provides approximately 4 times the peak concentration observed following the recommended dose, doravirine does not prolong the QT interval to any clinically relevant extent.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.